公开(公告)号：US08101653B2

公开(公告)日：2012-01-24

申请号：US10763393

申请日：2004-01-26

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K31/335 ,  A61K31/216 ,  A61K31/22 ,  A61K31/225

CPC classification number: C07C69/72 ,  A23L27/66 ,  A23L33/10 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/19 ,  A61K31/22 ,  A61K31/365 ,  A61K31/765 ,  C07B2200/07 ,  C07C67/14 ,  C07C67/46 ,  C07C67/465 ,  C07C69/675 ,  C07D323/00 ,  A23V2250/30

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

公开(公告)号：US5100677A

公开(公告)日：1992-03-31

申请号：US940333

申请日：1986-12-17

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K31/19 ,  A61K33/00 ,  A61K33/10 ,  A61K33/14 ,  A61M1/00 ,  A61M1/16 ,  A61M1/28

CPC classification number: A61M1/287 ,  A61K31/19 ,  A61K33/10 ,  A61K33/14 ,  A61M1/1654

Abstract: Processes and compositions are provided for accomplishing fluid therapy using the anions l-lactate, pyruvate, d-betahydroxybutyrate, acetoacetate, or mixtures of such. The racemic d,l-lactate or acetate anion mixtures heretofore used in fluids are now known not to be desirable because they cause adverse and toxic effects when administered to mammals.

Abstract translation: 提供了使用1-乳酸阴离子，丙酮酸盐，d-β-羟基丁酸盐，乙酰乙酸盐或其混合物来完成流体疗法的方法和组合物。 迄今为止用于流体的外消旋d，l-乳酸盐或乙酸盐阴离子混合物现在已知不是期望的，因为当施用于哺乳动物时它们引起不利和毒性作用。

公开(公告)号：US20090253781A1

公开(公告)日：2009-10-08

申请号：US12453471

申请日：2009-05-12

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K31/22 ,  A61K31/19 ,  C12N5/06 ,  A61K31/225 ,  C07C69/72 ,  A61K31/335 ,  A61P25/28 ,  A61P9/00 ,  A61P3/10 ,  A61P25/08

CPC classification number: A61K31/22 ,  A23L33/105 ,  A61K31/19 ,  A61K31/365 ,  C07B2200/07 ,  C07C67/14 ,  C07C67/46 ,  C07C69/72 ,  C07D323/00

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

Abstract translation: 提供了包含酮体和/或其代谢前体的组合物，其适用于给予人和动物，并且其特性包括（i）提高心脏效率，特别是使用葡萄糖的效率，（ii）提供 能源，特别是在糖尿病和胰岛素抵抗状态下，以及（iii）治疗由脑细胞损伤引起的疾病，特别是通过延迟或预防记忆相关脑区域的脑损伤，例如在阿尔茨海默病和类似病症中发现的。 这些组合物可以作为营养辅助剂，例如用于运动员，或用于治疗医疗状况，特别是与心脏功能降低，胰岛素抵抗和神经元损伤相关的那些。 本发明还提供了用于包含在本发明的组合物中的治疗方法和新的酯和聚合物。

公开(公告)号：US4663166A

公开(公告)日：1987-05-05

申请号：US748232

申请日：1985-06-24

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61M1/00 ,  A61K31/56 ,  A61K31/65 ,  A61K31/66 ,  A61K31/70 ,  A61K33/00 ,  A61K33/10 ,  A61K33/14 ,  A61M1/16 ,  A61K31/19

CPC classification number: A61K33/10 ,  A61K33/00 ,  A61K33/14 ,  A61M1/1654

Abstract: Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition, and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized, and cellular cofactor ratios are normalized, in a manner which decreases toxicity over prior art solutions. The solutions employ at least one of the following near-equilibrium couples: (a) bicarbonate/CO.sub.2 ; (b) 1-lactate/pyruvate; and (c) d-betahydroxybutyrate/acetoacetate.

Abstract translation: 提供电解质溶液，其可用于电解质和流体疗法，肠外营养和透析。 将Na：Cl比值归一化，将血浆和细胞pH值归一化，并以与现有技术溶液相比降低毒性的方式标准化细胞辅因子比。 解决方案采用以下近平衡对中的至少一种：（a）碳酸氢盐/ CO 2; （b）1-乳酸/丙酮酸盐; 和（c）d-β-羟基丁酸酯/乙酰乙酸酯。

公开(公告)号：US20120071548A1

公开(公告)日：2012-03-22

申请号：US13137906

申请日：2011-09-21

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K31/19 ,  A61P25/00 ,  A61P5/50 ,  A61P25/08 ,  A61P3/10 ,  C07C67/465 ,  A61K31/357 ,  C07C69/72 ,  C07C69/675 ,  C07C67/46 ,  C07C67/14 ,  A61P25/28 ,  A61K31/20

CPC classification number: C07C69/72 ,  A23L27/66 ,  A23L33/10 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/19 ,  A61K31/22 ,  A61K31/365 ,  A61K31/765 ,  C07B2200/07 ,  C07C67/14 ,  C07C67/46 ,  C07C67/465 ,  C07C69/675 ,  C07D323/00 ,  A23V2250/30

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

Abstract translation: 提供了包含酮体和/或其代谢前体的组合物，其适用于给予人和动物，并且其特性包括（i）提高心脏效率，特别是使用葡萄糖的效率，（ii）提供 能源，特别是在糖尿病和胰岛素抵抗状态下，以及（iii）治疗由脑细胞损伤引起的疾病，特别是通过延迟或预防记忆相关脑区域的脑损伤，例如在阿尔茨海默病和类似病症中发现的。 这些组合物可以作为营养辅助剂，例如用于运动员，或用于治疗医疗状况，特别是与心脏功能降低，胰岛素抵抗和神经元损伤相关的那些。 本发明还提供了用于包含在本发明的组合物中的治疗方法和新的酯和聚合物。

公开(公告)号：US6020007A

公开(公告)日：2000-02-01

申请号：US179880

申请日：1994-01-11

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K31/19 ,  A61K33/06 ,  A61K33/10 ,  A61K33/14 ,  A61M1/16 ,  A61M1/28 ,  C12N5/00 ,  A61K31/215 ,  A61K31/22 ,  A61K33/02

CPC classification number: A61K33/06 ,  A61K31/19 ,  A61K33/10 ,  A61K33/14 ,  A61M1/1654 ,  A61M1/287 ,  C12N5/0018 ,  C12N2500/12

Abstract: Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

公开(公告)号：US5719119A

公开(公告)日：1998-02-17

申请号：US53291

申请日：1993-04-26

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61K33/10 ,  A61K38/00

CPC classification number: A61K33/10

Abstract: Parenteral nutrition aqueous solutions are provided which preferably contain glutamine together with other organic nitrogen containing compounds. The respective concentrations of the compounds present in any given such solution are typically approximately multiples of the concentration of the same compounds as found in normal human plasma, and the respective mole ratios of various such compounds in any given such solution relative to one another are approximately the same mole ratio associated with the same compounds as found in normal human plasma. Processes for using such solutions are provided.

Abstract translation: 提供肠外营养水溶液，其优选含有谷氨酰胺与其它含有机氮的化合物。 存在于任何给定的这种溶液中的化合物的相应浓度通常是在正常人血浆中发现的相同化合物的浓度的近似倍数，并且在任何给定的这种溶液中各种这样的化合物相对于彼此的相应摩尔比约为 与在正常人血浆中发现的相同化合物相关的相同摩尔比。 提供了使用这些解决方案的过程。

公开(公告)号：US4929449A

公开(公告)日：1990-05-29

申请号：US940331

申请日：1986-12-17

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61J1/00 ,  A61J1/20 ,  A61K31/22 ,  A61K33/00 ,  A61K33/14

CPC classification number: A61J1/2093 ,  A61K33/00 ,  A61K33/14 ,  A61J1/10 ,  A61J1/2027

Abstract: Methods are provided for preparing just before administration unit doses of therapeutic solutions which contain redox active unstable and/or diffusable metabolites such as ketoacid, a sulfhydryl-containing amino acid, or carbon dioxide. The method involves preparing and storing an aqueous solution of stable components which may or may not contain carbon dioxide. A dry powder comprised of unstable components is also prepared and stored separately. These separate component compositions are packaged in, for example, individual chambers of a common sealed container which is so constructed as to permit the opening, by externally applied manual means or the like, of a passageway between such chambers at the time when usage is contemplated. Thus, a fresh solution in desired full dosage form is preparable just before administration. Improved container structures for practice of this method are also provided.

Abstract translation: 提供方法用于在施用单位剂量的含有氧化还原活性不稳定和/或可扩散代谢物如酮酸，含巯基的氨基酸或二氧化碳的治疗溶液之前进行制备。 该方法包括制备和储存稳定组分的水溶液，其可以含有或可以不含有二氧化碳。 由不稳定组分组成的干粉也分别制备并储存。 这些分开的组分组合物被包装在例如公共密封容器的单独的室中，其被构造成允许通过外部施加的手动装置等打开在使用期间这种室之间的通道 。 因此，所需全剂型的新鲜溶液可在给药前准备。 还提供了用于实践该方法的改进的容器结构。

公开(公告)号：US4663289A

公开(公告)日：1987-05-05

申请号：US747792

申请日：1985-06-24

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61M1/00 ,  A61K31/56 ,  A61K31/65 ,  A61K31/66 ,  A61K31/70 ,  A61K33/00 ,  A61K33/10 ,  A61K33/14 ,  A61M1/16 ,  C12N5/00 ,  A01N1/02

CPC classification number: A61K33/10 ,  A61K33/00 ,  A61K33/14 ,  A61M1/1654

Abstract: Processes and compositions are provided for in vitro use in tissue culture media (preferred), perfusion media, and incubation media. Thus, balanced salt solutions are provided wherein the milliequivalent ratio of sodium cations to chloride anions is normalized and wherein optionally at least one near-equilibrium couple is incorporated (bicarbonate.sup.- /carbon dioxide, L-lactate.sup.- /pyruvate.sup.-, and d-betahydroxybutyrate.sup.- /acetoacetate.sup.-. Regulation of intracellular and extracellular pH, and normalization of intracellular redox state and phosphorylation state is achievable.

Abstract translation: 提供了用于组织培养基（优选），灌注培养基和培养基中的体外应用的方法和组合物。 因此，提供了平衡的盐溶液，其中钠阳离子与氯化物阴离子的毫当量比归一化，并且其中任选地加入至少一个近平衡对（碳酸氢盐/二氧化碳，L-乳酸 - /丙酮酸盐和d-β-羟基丁酸盐 - /乙酰乙酸酯。细胞内和细胞外pH的调节和细胞内氧化还原状态和磷酸化状态的归一化是可以实现的。

公开(公告)号：US4649050A

公开(公告)日：1987-03-10

申请号：US747858

申请日：1985-06-24

Applicant: Richard L. Veech

Inventor： Richard L. Veech

IPC: A61M1/00 ,  A61K33/00 ,  A61K33/14

CPC classification number: A61K33/00

Abstract: The use of non diffusible organic polyionic materials in aqueous electrolyte solutions is taught wherein the electrolyte types and concentrations are suitable for use in treating living animal cells (including mammals and man). In these solutions, the Na:Cl ratio is normalizable without the use of unphysiological or demonstrably pathological amounts or ratios of small diffusible anions. Effective plasma expanders and plasma substitutes are provided. Near equilibrium couples may be incorporated if desired.

Abstract translation: 教导了在电解质水溶液中使用不可扩散的有机聚离子材料，其中电解质类型和浓度适用于处理活的动物细胞（包括哺乳动物和人）。 在这些解决方案中，Na：Cl比值是可以正常化的，而不使用非生理或显着的病理量或小扩散阴离子的比例。 提供有效的等离子体扩展器和等离子体替代品。 如果需要，可以并入近平衡对。